Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is a sponsor of Oncology Meeting Innovations’ 4thAnnual Summit on Hematologic Malignancies, which is being held March 30th – April 2nd, 2017 at the Fairmont Chateau Whistler in British Columbia, Canada. Dr. John Pagel, Chief of Hematologic Malignancies at the Swedish Cancer Institute will speak in the Emerging Drugs Showcase session titled, “Radioimmunotherapy in AML: Iomab-B and Actimab-A” on Saturday April 1, 2017.
The 4th Annual Summit on Hematologic Malignancies brings together translational researchers, clinical researchers and key community oncologists to address the challenges of the rapidly evolving area of oncology. The Summit is intended to foster discussion and debate on the evolution of treatment and features a focused approach towards individual patient populations through case-based discussions.
Actinium’s Executive Chairman, Sandesh Seth said, “Meetings such as this Summit on Hematologic Malignancies are vital as they afford us the opportunity to meet with physicians who are not only investigators in our trials but also physicians who can refer patients to our trials. Actinium is honored to have the opportunity to sponsor this event and we are thrilled that Dr. Pagel will be speaking on behalf of Iomab-B and Actimab-A to this fantastic audience.”
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company’s lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company’s second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.